EndoChoice names new board chairman, Ferring Pharmaceuticals to develop new IBD drug & more – 5 GI/endoscopy company key notes

Here are five recent news updates on gastroenterology and endoscopy companies.

Analysts with RBC Capital increased their price target of Boston Scientific to $20.

Ferring Pharmaceuticals and Institut Pasteur, a non-profit biomedical research center, are collaborating on the development novel drug development for the treatment of inflammatory bowel disease, according to a PMLive report.

EndoChoice named Scott Huennekens its chairman of the board.
http://www.endochoice.com/site/downloads/PR-15-009-1%20Scott%20Huennekens%20COB.pdf

Olympus warned European hospitals of infection risk linked to its TJF-Q180V duodenoscope approximately two years ago, but a similar warning was not released in the United States until recently.

Ritter Pharmaceuticals named Gerald T. Proehl the seventh member of its board of directors.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast